#United States #Dallas #Koya Medical #Lymphedema #Non-Pneumatic Compression

Multi-Society Endorsed Position Statement on Non-Pneumatic Compression in Lymphedema Management

In a significant advancement for the management of lymphedema, Koya Medical has recently published a multi-society endorsed position statement in the Journal of Vascular Surgery: Venous and Lymphatic Disorders. This statement strongly supports the clinical utility of non-pneumatic compression devices (NPCD) in treating not only lymphedema but also phlebolymphedema.

The position statement, which can be accessed through the DOI 10.1016/j.jvsv.2025.102356, is a collaboration among prominent societies including the American Venous Forum and the American Venous and Lymphatic Society. It distills the evidence accumulated from numerous clinical studies, presenting a compelling case for NPCD as a viable treatment alternative in compression therapy.

Clinical Evidence and Key Findings

The paper elaborates on findings from 11 clinical studies, two of which were significant randomized controlled trials (the NILE and TEAYS studies). Through rigorous comparisons of NPCD against advanced pneumatic compression devices (APCD), the results showcase a multitude of benefits:

• - Greater limb volume reduction: The NPCD was found to provide superior outcomes in decreasing limb volumes compared to traditional methods.
• - Improvements in quality of life: Patients reported statistically significant enhancements in quality of life indicators while using NPCD.
• - Higher adherence rates: The study highlighted that NPCD resulted in significantly higher rates of patient compliance.
• - No device-related adverse events: Notably, there were no reported adverse events related to the NPCD, underscoring its safety.

Particularly in the lower extremity cohort examined in the TEAYS study, NPCD was associated with fewer complications related to the disease when stacked against APCD, further emphasizing its clinical advantages.

Mechanistic Insights into NPCD

Koya Medical's NPCD represents an innovative approach that merges three well-established, evidence-based mechanisms of compression therapy:
1. Static Compression: Provides baseline pressure that aids in fluid management.
2. Sequential Gradient Compression: This promotes effective fluid movement through controlled pressure variation.
3. Muscle Pump Activation: Encouraging natural muscle movement enhances circulation and facilitates lymphatic drainage.

These mechanisms are integrated into a user-friendly, wearable device that ensures mobility during treatment, aligning with modern therapeutic practices and guidelines.

Future Implications for Clinical Practice

The authors of the position statement advocate for NPCD's consideration for patients who do not respond effectively to traditional conservative therapies. They also recommend that NPCD be included in future clinical guideline updates, reflecting the growing validation of this treatment approach.

Moreover, the statement calls for broader adoption of NPCD based on its substantial clinical evidence, reiterating the device's role in the ongoing evolution of lymphedema management.

About NPCD and Koya Medical

Koya Medical's Dayspring® non-pneumatic compression system is currently FDA-cleared for various edema conditions, including lymphedema and venous insufficiency. Founded in 2018 and based in Dallas, Koya Medical continues to innovate within the realm of venous and lymphatic disease management, focusing on improving patient outcomes through clinically validated technologies. As the landscape of lymphedema therapy evolves, the positive reception of NPCD signifies a transformative shift towards more effective patient care solutions.

In conclusion, this newly endorsed position statement and the evidence underscoring NPCD's efficacy herald a promising future for patients affected by lymphedema, as healthcare practices begin to embrace this advanced therapeutic option.